title: Caution with new oral hepatitis C drugs.
abstract: The hepatitis C field is living a revolution following the introduction of all-oral therapies that can cure most patients with short courses of direct-acting antiviral (DAA) combinations. Given that chronic hepatitis C affects globally around 20% of HIV persons, major attention has been focused on the HIV/HCV-coinfected population. Current evidence suggests that these patients depict cure rates of over 90%, similar to HCV-monoinfected individuals. Accordingly, current guidelines for hepatitis C therapy no longer separate mono- and coinfected subjects.
authors.affiliation: La Paz University Hospital & IdiPAZ, Madrid, Spain.
authors.forename: Vicente
authors.initials: V
authors.lastname: Soriano
authors.affiliation: La Paz University Hospital & IdiPAZ, Madrid, Spain.
authors.forename: Isabella
authors.initials: I
authors.lastname: Esposito
mesh_terms: D000998:Antiviral Agents / Q000009:adverse effects* / Q000627:therapeutic use*; D064420:Drug-Related Side Effects and Adverse Reactions / Q000453:epidemiology; D019698:Hepatitis C, Chronic / Q000188:drug therapy*; D006801:Humans; D011480:Protease Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use*
chemical_list: D000998:Antiviral Agents; D011480:Protease Inhibitors